MoneyDiscourse
← All companies

Health Care

5 companies compared on the lines they each report. Only figures more than one of them discloses appear here — a line only one company prints would read as a gap rather than a difference in disclosure.

37 comparable lines

Latest reported figure and its year-over-year change. Periods differ between companies — each reports on its own fiscal calendar.

LineABBVBMYLLYMRKPFE
Weighted-average diluted shares outstandingIncome statement1,772+0.0% · Q3 FY20262,047+0.3% · Q1 FY2026898,002−0.6% · Q4 FY20252,478−0.8% · Q3 FY20265,751+0.6% · Q3 FY2026
Diluted earnings per share attributable to AbbVie Inc.Income statement$2.37+2270.0% · Q3 FY2026$1.05−2.8% · Q3 FY2026$7.22+16.3% · Q3 FY2026$2.04−12.1% · Q3 FY2026$0.56−9.7% · Q3 FY2026
Adjusted diluted earnings per shareIncome statement$3.82+105.4% · Q3 FY2026$1.35−17.2% · Q3 FY2026$7.48+6.6% · Q3 FY2026−$1.28−157.7% · Q1 FY2026$0.87+0.0% · Q3 FY2026
Net earningsIncome statement$4.22bn+2144.7% · Q3 FY2026$2.68bn+8.8% · Q1 FY2026$6.45bn+15.5% · Q3 FY2026$5.07bn−12.4% · Q3 FY2026$3.24bn−8.4% · Q3 FY2026
Net revenuesIncome statement$17.4bn+10.3% · Q3 FY2026$13.07bn+6.9% · Q3 FY2026$24.4bn+38.6% · Q3 FY2026$18.09bn+4.7% · Q3 FY2026$16.58bn−0.4% · Q3 FY2026
Effective tax rateMargins—14.8%−49.8% · Q3 FY202623.3%+2.2% · Q3 FY20268.9%−37.3% · Q3 FY20263.9%+160.0% · Q3 FY2026
Effective tax rate (Non-GAAP)Margins—14.1%−36.8% · Q3 FY202624.0%+35.6% · Q3 FY202610.9%— · Q3 FY202614.0%+77.2% · Q3 FY2026
Gross margin ratioMargins75.4%— · Q3 FY202668.3%−5.0% · Q3 FY2026$20.46bn+40.2% · Q3 FY202672.9%−6.2% · Q3 FY2026—
Adjusted gross margin ratioMargins85.1%— · Q3 FY202668.4%−6.2% · Q3 FY2026$20.59bn+40.0% · Q3 FY202681.4%−0.6% · Q3 FY2026—
As adjusted (non-GAAP) after-tax earningsIncome statement$6.8bn+105.5% · Q3 FY2026—$6.68bn+5.8% · Q3 FY2026$6.16bn−4.5% · Q3 FY2026$4.99bn+0.7% · Q3 FY2026
Earnings before income tax expenseIncome statement$4.83bn+576.3% · Q3 FY2026$2.54bn−18.6% · Q3 FY2026—−$683m−113.7% · Q2 FY2026$3.39bn+1.5% · Q3 FY2026
Research and developmentIncome statement$2.57bn+10.7% · Q3 FY2026$2.37bn−6.4% · Q3 FY2026—$4.54bn+7.2% · Q3 FY2026$3.02bn+18.5% · Q3 FY2026
As adjusted (non-GAAP) R&DIncome statement$2.43bn+7.5% · Q3 FY2026$2.36bn−2.8% · Q3 FY2026—$4.53bn+13.4% · Q3 FY2026$2.94bn+18.3% · Q3 FY2026
Selling, general and administrativeIncome statement$4.09bn+14.5% · Q3 FY2026$1.7bn−5.0% · Q3 FY2026—$2.89bn+9.6% · Q3 FY2026$3.28bn+2.9% · Q3 FY2026
As adjusted (non-GAAP) SG&AIncome statement$3.69bn+8.1% · Q3 FY2026$1.7bn−5.0% · Q3 FY2026—$2.86bn+10.1% · Q3 FY2026$3.22bn+2.0% · Q3 FY2026
Cost of salesIncome statement——$3.93bn+30.8% · Q3 FY2026$4.89bn+26.9% · Q3 FY2026$4.03bn−3.5% · Q3 FY2026
Income tax provisionIncome statement—$374m−59.3% · Q3 FY2026—$492m−48.6% · Q3 FY2026$134m+162.0% · Q3 FY2026
As adjusted (non-GAAP) pre-tax earningsIncome statement$7.87bn+79.6% · Q3 FY2026$3.22bn−24.4% · Q3 FY2026—$550m— · Q2 FY2026—
Total Revenues - U.S.Segments—$9.07bn+8.9% · Q3 FY2026$15.1bn— · Q3 FY2026—$10.6bn−0.8% · Q3 FY2026
Acquired IPRDIncome statement—$1.56bn+146.1% · Q3 FY2026$4.18bn+537.3% · Q3 FY2026——
Cost of products soldIncome statement$4.29bn−19.2% · Q3 FY2026$4.15bn+20.7% · Q3 FY2026———
As adjusted (non-GAAP) cost of products soldIncome statement$2.6bn+2.1% · Q3 FY2026$4.13bn+24.8% · Q3 FY2026———
Non-GAAP Cost of salesIncome statement———$3.36bn+7.4% · Q3 FY2026$3.84bn−3.4% · Q3 FY2026
EliquisSegments—$4.69bn+25.2% · Q3 FY2026——$2.52bn+25.2% · Q3 FY2026
Income before income taxesIncome statement——$8.27bn+64.0% · Q4 FY2025$5.56bn−17.6% · Q3 FY2026—
Income tax expenseIncome statement$609m+15.8% · Q3 FY2026—$1.96bn+18.5% · Q3 FY2026——
Income tax provision (Non-GAAP)Income statement—$723m+10.9% · Q1 FY2026—$882m— · Q2 FY2026—
Total Revenues - Int'lSegments—$4bn+2.6% · Q3 FY2026——$5.98bn+0.3% · Q3 FY2026
Net earnings attributable to AbbVie Inc.Income statement$4.22bn+2167.7% · Q3 FY2026$2.16bn−1.8% · Q3 FY2026———
OncologySegments$1,696bn— · Q3 FY2026———$4.33bn+9.9% · Q3 FY2026
Operating earningsIncome statement$6.27bn+229.1% · Q3 FY2026—$8.61bn+16.9% · Q3 FY2026——
Operating margin ratioMargins36.0%— · Q3 FY202629.1%+63.5% · Q4 FY2025———
Adjusted operating margin ratioMargins48.7%— · Q3 FY202634.8%+1.5% · Q4 FY2025———
Other (income)/expense, netIncome statement—$307m+384.3% · Q3 FY2026—$27m+111.3% · Q3 FY2026—
Other (income)/expense, net (Non-GAAP)Income statement—$93m+145.1% · Q3 FY2026—$420m+296.2% · Q3 FY2026—
Research and developmentIncome statement—$2.59bn−19.0% · Q4 FY2025$4.25bn+22.5% · Q3 FY2026——
Net revenues U.S.Segments$12.86bn— · Q2 FY2026—$14.4bn— · Q2 FY2026——

Data from company filings. Not investment advice.